Phase IV clinical trial of CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet.

Phase IV clinical trial of CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet. - Evaluation of safety in patients with both Japanese cedar pollinosis and HDM-induced allergic rhinitis.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223956

Enrollment

100

Registered

2018-06-25

Start date

2018-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

investigational material(s) Generic name etc : CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet INN of investigational material : - Therapeutic category code : 449 Other antiallergic agents Dosage a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with both cedar pollen and HDM-specific IgE : class 2 or more. 2) Patients who have a clinical history of cedar pollinosis in 2017 and 2018 cedar pollen seasons. 3) Patients with positive nasal provocation test (HDM).

Exclusion criteria

Exclusion criteria: 1) Patients who have received specific immunotherapy for cedar pollinosis or HDM in history. 2) Patients who have severe asthma. 3) Patients who have food allergy, drug allergy or oral allergy syndrome.

Design outcomes

Primary

Measure	Time frame
safety Incidences of adverse event and IMP-related adverse event	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026